Xeleris 4.0 - Nuclear Medicine - Molecular Imaging

Molecular imaging has the distinct ability to make visible what could normally be invisible. Beyond that, it has the ability to measure it. This combination is what makes molecular imaging uniquely positioned to enable the search for true discovery.

A true discovery is different. It provides reproducible evidence to permit greater understanding. More than an observation, it is proof. And because it is reproducible, it is relatable, which means it could potentially transcend an individual and have a lasting impact for all.

To make a true discovery in nuclear medicine, the applications you use to interpret and communicate information are just as important as the tracers used to highlight that information and the technology used to capture it. In fact, it's these final measurable results that you ultimately require. To make the true discovery that helps you deliver the best outcome to the patient, or potentially impact the standard of care for all patients, you need the accuracy and consistency of absolute quantitation.

Xeleris^TM 4.0 is the next generation of our proven workstation for nuclear medicine. In the past, Xeleris led the way with mobilized capabilities that gave you accessible, easy-to-use tools to enhance productivity. With your guidance, we designed Xeleris 4.0 to deliver modern, quantitative applications for nuclear medicine; applications that give you the certainty of absolute quantitation in customizable, easy-to-read reports across multiple care areas.

Whether you are analyzing the brain, the heart, the lungs or any other organ of interest; if the decisions you make are better informed because we helped you find measurable true discoveries, then we have accomplished our mission with Xeleris 4.0.

Referring physicians rely on you to provide results that will inform their decisions; specific decisions that influence treatment strategies. The more accurate your results, the more specific your care can be. In the past, you relied on visual cues to provide an assessment of relative uptake leading to a higher rate of equivocal exams and indeterminate results. What referring physicians want are the numerical values to strengthen the quality of your nuclear medicine reports.

Xeleris 4.0 is leading the way from relative to absolute quantitation in nuclear medicine. Until now, the quantitative value of nuclear medicine was limited by the technology used to produce it. By leveraging breakthrough SPECT and SPECT/CT technology, we developed a collection of simple tools that combine relative and absolute quantitation. These tools provide a key selection of quantitative applications to help referring physicians manage complex diseases with measurable results.

A NEW ERA IN NUCLEAR MEDICINE

Accurately diagnose neurodegenerative diseases with Q.Brain

Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung

Confidently classify patients eligible for lung resection surgeries with Q.Lung

Quantitate tracer uptake across any lesion or organ with Q.Metrix

Leverage the power of CZT to calculate blood flow measurements with Alcyone CFR

Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of I-123 loflupane SPECT data with DaTQUANT^TM

Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit

Early detection of neurodegenerative disease is crucial to lessening the burden and cost of these diseases. The neuropathology of dementias can precede clinical symptoms by several years, but the challenge has been finding a way to accurately diagnose dementia as early as possible.

Patterns are an important part of differential diagnosis for neurodegenerative disease. The more sensitive an application is to detecting and visualizing patterns, the more quickly patients can be put on the correct treatment pathway. Q.Brain standardizes individual brain shapes through registration to a standard atlas while preserving functional information. Numeric uptake values are added to reports and compared to a normal patient database, since visual inspections or volume-of-interest techniques may not be sufficient for accurate diagnosis.

ESTABLISH CARE EARLY AND ACCURATELY

Provide specific indications for the differential diagnosis
of dementia, traumatic brain injuries, epilepsy and
other complex brain dysfunctions

Improve communication among physicians and care
teams, enhancing the value of nuclear medicine in the management of complex brain diseases

Give patients and their families the peace of mind of a definitive diagnosis, eliminating the frustration caused
by endless diagnostic testing

3D SSP images. Early and Late acquisitions. Late acquistion is post Diamox injection.

SPECT and MR fused images with quantitative analysis: uptakes and z-scores across all 26 regions of the brain.

SPECT/CT is a highly sensitive and specific diagnostic tool for pulmonary embolism assessment. It is a low dose alternative to CTPA with no contrast related complications and is more accurate than planar VQ studies. With SPECT/CT, we can reduce the overall radiation dose by 80 percent and up to 96 percent for breast tissue, when compared to a CTPA. Additionally, hybrid imaging increases the sensitivity to 97 percent and specificity to 100 percent. With Q.Lung, you can now accurately display both ventilation and perfusion in an easily interpretable review screen, integrated with the lung atlas, which can be customized to your reading preferences. It also helps to easily identify uptake mismatches and automatically calculates its quotient for a more effective way to diagnose pulmonary embolism.

Ventilation, Perfusion and Quotient images

THE GREATEST RESULT OF ALL

Reduce the 5-10 percent of preventable hospital deaths annually attributed to the misdiagnosis of pulmonary embolism

For important procedures like lung resection, a reliable assessment of post-operative lung function is essential. With 1.5 million lung cancer deaths a year, uncertain estimations provided by current planar imaging techniques are not enough. It's the difference between successfully performing a life-saving procedure and denying that procedure to a good candidate.

Breakthrough SPECT/CT technology provides a more accurate assessment of lobar perfusion. Q.Lung combines both anatomy and function with automatic and semi-automatic segmentation tools that help accurately quantitate lobe perfusion relative to the rest of the lung anatomy. The result is a more accurate evaluation of ppoFEV₁ to confidently inform the outcome of lung or lobe resection surgery.

Lung Perfusion Quantitation

RESULTS THAT MATTER

Influence treatment strategies with definitive
and actionable results

Provide meaningful and invaluable pre-surgical assessments

Until now, nuclear medicine has relied on relative qualitative assessments for diagnosis and treatment monitoring. As one of our first quantitative applications, Q.Metrix marked the first step in our vision to bringing quantitative accuracy to nuclear medicine.

Q.Metrix quantitates tracer uptake across any lesion and any organ. Using SPECT and CT segmentation tools, it defines regions of interest and computes volumes of interest for uptake measurements¹. It leverages the system's sensitivity with scan parameters and patient demographics to calculate a scaling factor that converts qualitative data into absolute quantitative values. The result is a SPECT SUV value that enables you to accurately monitor response to treatment.

¹Quantitate volumes greater than 5.5 cc within +/- 10 percent of deviation.

SIMPLE TOOLS TO START AND ADAPT TREATMENT

Measure treatment response with empirical values

Personalize treatment with accurate assessment of
disease progression

When it comes to the heart, relative quantitative results aren't enough. Current SPECT MPI studies use the area of highest myocardial activity as a reference point for the rest of the perfusion study. If that reference point is also abnormal, it compromises the accuracy of the entire study. In addition, triple vessel disease (balanced ischemia) and microvascular disease don't always result in an abnormal MPI exam. For years, PET has been a well-established gold standard for MBF exams, but it can be limited by cost and accessibility. Recent advancements in SPECT technology have made it possible to enhance the clinical value of nuclear cardiology.

Alcyone CFR leverages highly-sensitive Alcyone technology in our fully-stationary, solid state Discovery^TM NM530c and Discovery NM/CT 570 systems. It calculates coronary flow reverse and myocardial blood flow from a dynamic SPECT acquisition. In addition, it provides absolute quantitative results for both global and regional blood flow. With a wider availability of low cost SPECT tracers, previously limited to PET technologies, Alcyone CFR provides a real opportunity to explore the benefits of SPECT.

GROW WITH NUCLEAR CARDIOLOGY

Research protocol development with a potential for
stress-only acquisitions, dose reduction techniques
and prognostic outcomes

Expand the confidence in, and size of, your nuclear cardiology practice

A measurable result is an actionable result. It gives you the assurance to determine the best course of treatment and the confidence to adapt your care. Results that can be used to better inform the decisions you make for each patient, or to inform the research that will develop more specific indications for imaging equipment and radiopharmaceuticals.

Our vision for molecular imaging is to provide you with the important instruments you need to see and the ability to prove what is seen, and often not seen. It's why we committed ourselves to bringing you quantitative applications with Xeleris 4.0.

Let Xeleris 4.0 guide your path to your next true discovery.

You Are Changing Sites

GE Healthcare

Sorry, your search for: did not find any results

Related

DEMOS ON DEMAND